Skip to content
MarketScale
‹ Back to IndustriesSciences

Why Solid-State Lasers Have Replaced Traditional Gas Lasers for Most Applications

Lasers were once considered too highly specialized and expensive to be useful anywhere but in the laboratory. Over the years, however, as the devices have become smaller, more reliable, and less expensive, lasers have been widely adopted in applications as varied as surgery and welding, as well as in industries like military and aerospace. Now,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
Why Solid-State Lasers Have Replaced Traditional Gas Lasers for Most Applications

Key takeaways

01

Lasers were once considered too highly specialized and expensive to be useful anywhere but in the laboratory.

02

Over the years, however, as the devices have become smaller, more reliable, and less expensive, lasers have been widely adopted in applications as varied as surgery and welding, as well as in industries like military and aerospace.

Lasers were once considered too highly specialized and expensive to be useful anywhere but in the laboratory. Over the years, however, as the devices have become smaller, more reliable, and less expensive, lasers have been widely adopted in applications as varied as surgery and welding, as well as in industries like military and aerospace. Now, small, powerful, cost-effective solid-state lasers have replaced traditional gas lasers in many systems. Let’s take a look.

Lasers That Excite

There are five general categories of lasers: gas, liquid, plasma, semiconductor, and solid-state. Both semiconductor and solid-state lasers use a solid media, but in solid-state lasers, this medium is typically made from crystal, glass, or ceramics. This material acts as a host to which a dopant is added – usually a rare earth metal. This ionic material is then excited by optical pumping to produce the light that powers the laser.

Solid-State Lasers Offer Big Power in a Compact Package

For decades, air-cooled argon lasers have been successfully used in a wide variety of applications, but solid-state devices are becoming more popular. Significant progress has been made in recent years in generating new emission wavelengths and tunable sources of laser radiation from these devices. Today, the power, accuracy, and beam quality of solid-state lasers are on a par with those of argon lasers. And although argon lasers have an expected lifespan of 10,000 hours, preliminary findings show solid-state lasers may offer up to twice that. This can make them a more cost-effective option in the long term.

In addition, solid-state lasers are more rugged and compact than gas lasers, making them ideal for a number of applications, such as in medical devices. The biggest advantage, however, may be their energy efficiency. An air-cooled ion laser typically uses a kilowatt or more of power to produce 10 to 20 mW of blue light. The energy requirements of solid-state lasers are usually measured in the tens of watts or less. Solid-state lasers can also be programmed to release ultrashort pulses, which also greatly improves their efficiency and performance.

From Welding to Surgery: The Many Uses of Solid-State Lasers

Solid-state lasers are being adopted in a wide variety of industries and applications. In manufacturing and materials processing, they are used for welding, as well as marking, drilling, and cutting operations. In the medical field, they can be used for delicate procedures such as skin treatments and tattoo removal, or as a scalpel in tumor ablation and laser eye surgery. The military and aerospace industries are also using solid-state lasers for weapon systems and as detonation devices. These versatile devices are also used to conduct research in particle physics, material science, and nuclear power.

Fiberguide Industries Provides a Powerful Link for Solid-State Laser Applications

As solid-state laser technology continues to advance, more and more applications will take advantage of these devices. For more than three decades Fiberguide Industries has been a reliable, long-term, strategic partner with OEM manufacturers in providing efficient, cost-effective, practical fiber optic solutions engineered to meet their specific needs. Fiberguide is proud to be part of the solid-state laser revolution by offering High Power Assemblies that use High Power SMA and FD-80 connectors to provide a fiber optic link between the laser source and the target.

Read more at fiberguide.com

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences